| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| E M Williamson, F J Evan. Cannabinoids in clinical practice. Drugs. vol 60. issue 6. 2001-04-12. PMID:11152013. |
the relatively slow elimination from the body of the cannabinoids has safety implications for cognitive tasks, especially driving and operating machinery; although driving impairment with cannabis is only moderate, there is a significant interaction with alcohol. |
2001-04-12 |
2023-08-12 |
Not clear |
| P Lorenzo Fernánde. [Potential therapeutic usefulness of cannabis and cannabinoids]. Anales de la Real Academia Nacional de Medicina. vol 117. issue 3. 2001-04-12. PMID:11205042. |
[potential therapeutic usefulness of cannabis and cannabinoids]. |
2001-04-12 |
2023-08-12 |
Not clear |
| P Lorenzo Fernánde. [Potential therapeutic usefulness of cannabis and cannabinoids]. Anales de la Real Academia Nacional de Medicina. vol 117. issue 3. 2001-04-12. PMID:11205042. |
diseases in which cannabis and cannabinoids have demonstrated some medicinal putative properties are: nausea and vomiting associated with cancer chemotherapy, muscle spasticity (multiple sclerosis, movement disorders), pain, anorexia, epilepsy, glaucoma, bronchial asthma, neuroegenerative diseases, cancer, etc. |
2001-04-12 |
2023-08-12 |
Not clear |
| M Guzmán, I Galve-Roperh, C Sánche. Ceramide: a new second messenger of cannabinoid action. Trends in pharmacological sciences. vol 22. issue 1. 2001-03-29. PMID:11165667. |
cannabinoids, the active components of cannabis sativa (marijuana), and their endogenous counterparts exert their effects by binding to specific g(i/o)-protein-coupled receptors that modulate adenylyl cyclase, ion channels and extracellular signal-regulated kinases. |
2001-03-29 |
2023-08-12 |
Not clear |
| A F Hoffman, C R Lupic. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. Journal of neurophysiology. vol 85. issue 1. 2001-02-15. PMID:11152707. |
taken together, these data suggest that cannabinoids and opioids differentially modulate inhibitory and excitatory synaptic transmission in the nac and that the abuse liability of marijuana may be related to the direct actions of cannabinoids in this structure. |
2001-02-15 |
2023-08-12 |
rat |
| G Kunos, Z Járai, S Bátkai, S K Goparaju, E J Ishac, J Liu, L Wang, J A Wagne. Endocannabinoids as cardiovascular modulators. Chemistry and physics of lipids. vol 108. issue 1-2. 2001-01-11. PMID:11106789. |
cannabinoids, the bioactive constituents of the marijuana plant and their synthetic and endogenous analogs cause not only neurobehavioral, but also cardiovascular effects. |
2001-01-11 |
2023-08-12 |
Not clear |
| L De Petrocellis, D Melck, T Bisogno, V Di Marz. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chemistry and physics of lipids. vol 108. issue 1-2. 2001-01-11. PMID:11106791. |
the long history of the medicinal use of cannabis sativa and, more recently, of its chemical constituents, the cannabinoids, suggests that also the endogenous ligands of cannabinoid receptors, the endocannabinoids, and, particularly, their derivatives may be used as therapeutic agents. |
2001-01-11 |
2023-08-12 |
Not clear |
| S O Jacobsson, E Rongård, M Stridh, G Tiger, C J Fowle. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochemical pharmacology. vol 60. issue 12. 2001-01-11. PMID:11108795. |
in the present study, the effects of the combination of tamoxifen ((z)-2[p-(1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylamine citrate) and three cannabinoids (delta(9)-tetrahydrocannabinol [delta(9)-thc], cannabidiol, and anandamide [aea]) upon the viability of c6 rat glioma cells was assessed at different incubation times and using different culturing concentrations of foetal bovine serum (fbs). |
2001-01-11 |
2023-08-12 |
human |
| C W Vaughan, M J Christi. An analgesic role for cannabinoids. The Medical journal of Australia. vol 173. issue 5. 2001-01-11. PMID:11130354. |
this discovery has led pharmacologists to explore the potential of synthetic cannabinoids to selectively target chronic pain disorders without producing the side effects associated with cannabis. |
2001-01-11 |
2023-08-12 |
human |
| A A Izzo, N Mascolo, F Capass. Forgotten target for marijuana: the endocannabinoid system in the gut. Trends in pharmacological sciences. vol 21. issue 10. 2000-12-05. PMID:11203389. |
forgotten target for marijuana: the endocannabinoid system in the gut. |
2000-12-05 |
2023-08-12 |
Not clear |
| I S Lurie, R P Meyers, T S Conve. Capillary electrochromatography of cannabinoids. Analytical chemistry. vol 70. issue 15. 2000-11-15. PMID:11013726. |
baseline separation of seven cannabinoids (cannabigerol, cannabidiol, cannabinol, delta-9-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, cannabichromene, delta-9-tetrahydrocannabinolic acid) is obtained using a 3-micron cec hypersil c18 capillary with an acetonitrile/phosphate (ph 2.57) mobile phase. |
2000-11-15 |
2023-08-12 |
Not clear |
| P J Mclaughlin, C E Delevan, S Carnicom, J K Robinson, J Brene. Fine motor control in rats is disrupted by delta-9-tetrahydrocannabinol. Pharmacology, biochemistry, and behavior. vol 66. issue 4. 2000-11-07. PMID:10973519. |
evidence has suggested that cannabinoids such as thc, the active ingredient in marijuana, cause deficits in motor control and the production of movement. |
2000-11-07 |
2023-08-12 |
rat |
| J F Cheer, C A Marsden, D A Kendall, R Maso. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience. vol 99. issue 4. 2000-11-07. PMID:10974429. |
the maintained increase in da drive elicited by the potent cannabinoid agonist hu210 in the in vitro ventral tegmental circuit could explain some of the behavioural properties of cannabinoids, such as the lack of tolerance for the psychotropic effects of marijuana seen in human users. |
2000-11-07 |
2023-08-12 |
human |
| J Tytgat, M Van Boven, P Daenen. Cannabinoid mimics in chocolate utilized as an argument in court. International journal of legal medicine. vol 113. issue 3. 2000-10-12. PMID:10876983. |
a case is presented involving chocolate cannabinoid mimics which have been utilized in court by the defendant's lawyer in order to clear the accused of smoking and dealing in marijuana after he was found positive for cannabis in a routine urine immunoassay screening test. |
2000-10-12 |
2023-08-12 |
Not clear |
| Di Marzo, T Bisogno, L De Petrocelli. Endocannabinoids: new targets for drug development. Current pharmaceutical design. vol 6. issue 13. 2000-09-25. PMID:10903398. |
the possible therapeutic use of marijuana s active principles, the cannabinoids, is currently being debated. |
2000-09-25 |
2023-08-12 |
Not clear |
| S L Palmer, A D Khanolkar, A Makriyanni. Natural and synthetic endocannabinoids and their structure-activity relationships. Current pharmaceutical design. vol 6. issue 13. 2000-09-25. PMID:10903399. |
these new developments have also provided an opportunity to examine the physiological and biochemical events underlying the use and abuse of cannabis as well as elucidating the biological role of the endogenous cannabinoid ligands (endocannabinoids). |
2000-09-25 |
2023-08-12 |
Not clear |
| A H Lichtman, J Peart, J L Poklis, D T Bridgen, R K Razdan, D M Wilson, A Poklis, Y Meng, P R Byron, B R Marti. Pharmacological evaluation of aerosolized cannabinoids in mice. European journal of pharmacology. vol 399. issue 2-3. 2000-09-22. PMID:10884513. |
the reemergence on the debate of the use of marijuana for medicinal purposes has been the impetus for developing an acceptable delivery form of aerosolized cannabinoids. |
2000-09-22 |
2023-08-12 |
mouse |
| A H Lichtman, J Peart, J L Poklis, D T Bridgen, R K Razdan, D M Wilson, A Poklis, Y Meng, P R Byron, B R Marti. Pharmacological evaluation of aerosolized cannabinoids in mice. European journal of pharmacology. vol 399. issue 2-3. 2000-09-22. PMID:10884513. |
the goals of the present study were to: (1) develop and characterize the physical properties of an aerosolized form of delta(9)-tetrahydrocannabinol (delta(9)-thc), the major psychoactive constituent present in marijuana; and (2) assess the pharmacological effects of cannabinoid inhalation in mice. |
2000-09-22 |
2023-08-12 |
mouse |
| S E Strau. Immunoactive cannabinoids: therapeutic prospects for marijuana constituents. Proceedings of the National Academy of Sciences of the United States of America. vol 97. issue 17. 2000-09-19. PMID:10931962. |
immunoactive cannabinoids: therapeutic prospects for marijuana constituents. |
2000-09-19 |
2023-08-12 |
Not clear |
| F Nava, G Carta, A M Battasi, G L Gess. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. British journal of pharmacology. vol 130. issue 6. 2000-09-13. PMID:10903956. |
our findings suggest that impairment of working memory and inhibition of hippocampal extracellular acetylcholine concentration are mediated by the concomitant activation of d(2) dopamine and cb(1) cannabinoid receptors, and that d(2) dopamine receptor antagonists may be useful in the treatment of the cognitive deficits induced by marijuana. |
2000-09-13 |
2023-08-12 |
rat |